Press releases
-
-
-
Internal link ProQR Announces Results for the First Quarter of 2018
-
Internal link ProQR Announces Conference Presentations for Axiomer® RNA Editing Technology and QR-313 for DEB
-
Internal link ProQR Provides Enrollment Update on QR-110 Clinical Trial and Highlights Ophthalmology Presentations at ARVO
-
Internal link ProQR Announces Annual Meeting of Shareholders
-
Internal link ProQR Appoints ADAR Expert Dr. Peter A. Beal to Scientific Advisory Board to Focus on Axiomer® RNA A-to-I Editing Technology
-
Internal link ProQR to Present at Two Upcoming Conferences
-
Internal link ProQR to Present at Upcoming Investor Conference
-
Internal link ProQR Announces Results for the Fourth Quarter and Full Year 2017 and Provides Business Update
-
-
-
-
Internal link ProQR and Galapagos Announce Research Collaboration on Fibrosis Targets Using ProQR’s Axiomer® technology
-
-
Internal link ProQR Receives Orphan Drug Designation from EMA for Drug Candidate QR-313 for Dystrophic Epidermolysis Bullosa
-
-
Internal link ProQR Announces Results for the Third Quarter of 2017
-
-
-
Internal link ProQR Doses First LCA 10 Patient in Clinical Trial of QR-110, ProQR’s Lead Program for Genetic Blindness
-
-
Internal link ProQR to Present at EuroTIDES Conference
-
Internal link ProQR Announces Management Change and Key Promotions
-
Internal link ProQR Announces Presentations and Investor & Analyst Event at the North American Cystic Fibrosis Conference